Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Lung Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 50Cyclophosphamide 50Mycophenolic Acid 36Cyclosporine 33Busulfan 33Whole-Body Irradiation 32Peripheral Blood Stem Cell Transplantation 31Antilymphocyte Serum 24fludarabine 21Cord Blood Stem Cell Transplantation 21Tacrolimus 20Cytarabine 19Filgrastim 18Melphalan 17Radiotherapy 15Methylprednisolone 13Methotrexate 13Thiotepa 10Granulocyte Colony-Stimulating Factor 10Etoposide 9Cyclosporins 7Azacitidine 7thymoglobulin 5sargramostim 5Idarubicin 5Clofarabine 5Arsenic Trioxide 5Transplantation 4Sirolimus 4Gemtuzumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Anemia, Refractory, with Excess of Blasts × Drug Screening Assays, Antitumor × Clear all
NCT01872819 2018-07-11

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

University of Washington

Phase NA Completed
16 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡